Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome

Dina Dadabhoy
Northwest Rheumatology Specialists

Leslie J. Crofford
University of Kentucky, ljcrof2@email.uky.edu

Michael Spaeth
Center for Clinical Rheumatology Research, Germany

I. Jon Russell
University of Texas Health Science - San Antonio

Daniel J. Clauw
University of Michigan - Ann Arbor

Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub

Part of the Medicine and Health Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation
Dadabhoy, Dina; Crofford, Leslie J.; Spaeth, Michael; Russell, I. Jon; and Clauw, Daniel J., "Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome" (2008). Internal Medicine Faculty Publications. 25.
https://uknowledge.uky.edu/internalmedicine_facpub/25

This Review is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome

Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/ar2443

Notes/Citation Information
Published in Arthritis Research & Therapy, v. 10, 211.

© 2008 BioMed Central Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This review is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/25
Abstract
Researchers studying fibromyalgia strive to identify objective, measurable biomarkers that may identify susceptible individuals, may facilitate diagnosis, or that parallel activity of the disease. Candidate objective measures range from sophisticated functional neuroimaging to office-ready measures of the pressure pain threshold. A systematic literature review was completed to assess highly investigated, objective measures used in fibromyalgia studies. To date, only experimental pain testing has been shown to coincide with improvements in clinical status in a longitudinal study. Concerted efforts to systematically evaluate additional objective measures in research trials will be vital for ongoing progress in outcome research and translation into clinical practice.

Introduction
Fibromyalgia (FM) is a chronic condition characterized by widespread pain and tenderness on examination, along with symptoms of nonrestorative sleep, fatigue, and cognitive difficulties. Recent familial studies have suggested an underlying genetic susceptibility on which environmental factors trigger the expression of symptoms [1,2]. Despite the myalgias that patients experience, no abnormality in muscle has been reliably found [3]. Instead, aberrant pain and sensory processing probably caused by alterations in the central nervous system function are being consistently recognized in FM and related syndromes. Investigations into the autonomic nervous system and the hypothalamic–pituitary–adrenal axis also suggest a role of these stress–response systems in vulnerability to FM or in symptom expression in FM.

Our improved understanding of FM has stimulated the search for biomarkers to be used to identify individuals susceptible to the syndrome, for the diagnosis of FM, for objective measures of disease activity, or as surrogate endpoints of clinical trials. Using an expert panel from the FM workshop of the Outcome Measures in Rheumatology (OMERACT), a list of potential objective measures was first developed. Studies evaluating the measures were then methodically compiled by systematic review of the literature using a search for FM and the specific objective measure of interest. The databases searched included MEDLINE (1966 to 2006), PubMed (1966 to 2006), CINAHL (1982 to 2006), EMBASE (1988 to 2006), Healthstar (1975 to 2000), Current Contents (2000 to 2006), Web of Science (1980 to 2006), PsychInfo (1887 to 2006), Science Citation Indexes (1996 to 2006), and/or Cochrane Collaboration Reviews (1993 to 2006). The resulting published studies were used as the basis for the review.

Genetics
Increasing evidence supports a genetic predisposition to FM. First-degree relatives of individuals with FM display an eightfold greater risk of developing the syndrome than those in the general population [1]. As such, a genetic study using multicase families has been completed that identified an HLA linkage not yet replicated [4].

Polymorphisms in the serotonergic 5-hydroxy tryptamine 2A receptor (T/T phenotype), the serotonin transporter, the dopamine 4 receptor and the catecholamine o-methyl transferase enzyme have also been evaluated in patients with FM [5-10]. Notably, these polymorphisms all affect the metabolism or transport of monoamines, compounds that have a critical role in both sensory processing and the human stress response. With the exception of the catecholamine o-methyl transferase finding and the dopamine-4-receptor gene polymorphism, however, which have not been replicated or
refuted, the other findings initially noted were generally not found in subsequent studies [4-10]. In some cases, the findings in FM were found when all individuals with this disorder were studied, but not when individuals free of psychiatric comorbidities were studied, suggesting that some of the above findings may track more closely with psychiatric comorbidity than inherent features of FM. Other candidate genes evaluated but not shown to be associated with FM are presented in Table 1.

### Evoked (experimental) pain measures

Even before the establishment of the American College of Rheumatology criteria for FM in 1990, which require both widespread pain and tenderness, investigators have used psychophysical pain testing to learn more about the nature of this condition. In fact, the early findings that the tenderness in FM was detectable throughout the body, rather than just confined to areas of tender points or muscle, was a hallmark finding that led investigators to believe this was a central nervous system pain amplification syndrome [11]. These measures are only relatively objective since they require patient self-report, but tender points do clearly measure a phenomenon that is independent from spontaneous, clinical pain.

Numerous experimental pain studies have evaluated methods of quantifying the sensory experience of pain. Various groups have assessed the pain threshold and have attempted to quantify the pain experience in FM. A review of the investigated modalities gives the greatest support for the use of the tender point intensity/index, pressure pain thresholds, or heat pain thresholds as objective measures of the degree of hyperalgesia (increased pain to normally painful stimuli) and allodynia (pain in response to normally nonpainful stimuli) of an individual. Another consistent finding has been an absence of descending endogenous analgesic activity in FM.

### Tender point count

The American College of Rheumatology criteria for FM require that an individual has a certain degree of tenderness. A tender point count is performed by applying 4 kg pressure manually to 18 predefined tender points, and then asking the patient whether these areas are tender. A positive response is considered a tender point; if an individual has 11 tender points or more, this element of the case definition is satisfied.

The apparent close link between tenderness and FM has been well studied in both clinical trials of new therapies and in mechanistic studies. In a number of longitudinal randomized, placebo-controlled trials, improvements in clinical pain have corresponded with a significant change in tender point counts or in the tender point index [12-14]. In contrast, other studies did not show a correspondence between improvements in clinical pain and tender point counts [15-20].

| Reference | Year of study | Number of subjects | Number of control individuals | Objective measure | Findings |
|-----------|--------------|-------------------|-------------------------------|------------------|----------|
| Bondy and colleagues [5] | 1999 | 168 FMS | 115 | 5-HT2A, T102C polymorphism | Different from control, but not significant for specific allele |
| Gürsoy and colleagues [6] | 2001 | 58 FMS | 58 | 5-HT2A, T102C polymorphism | Not significant |
| Gürsoy and colleagues [7] | 2003 | 61 FMS | 61 | COMT haplotype | Over-representation of LL variant (low activity). Similar to migraine and TMD |
| Offenbaecher and colleagues [8] | 1999 | 62 FMS | 110 | 5-HTT | One positive for over-representative SS genotype, one negative study. Suggestion that any association might be related to comorbid psychology |
| Gürsoy [9] | 2002 | 53 FMS | 60 mentally healthy | 5-HTT | Linkage to HLA |
| Yunus and colleagues [4] | 1999 | 40 multicase families | HLA | | |
| Buskila and colleagues [10] | 2004 | | | Dopamine D4 receptor polymorphism | Decrease in the frequency of the seven-repeat allele in exon III of the D4 receptor gene associated with fibromyalgia. Finding associated with low novelty-seeking personality |

**Table 1**

| Genetics in fibromyalgia |

| Reference | Year of study | Number of subjects | Number of control individuals | Objective measure | Findings |
|-----------|--------------|-------------------|-------------------------------|------------------|----------|
| Bondy and colleagues [5] | 1999 | 168 FMS | 115 | 5-HT2A, T102C polymorphism | Different from control, but not significant for specific allele |
| Gürsoy and colleagues [6] | 2001 | 58 FMS | 58 | 5-HT2A, T102C polymorphism | Not significant |
| Gürsoy and colleagues [7] | 2003 | 61 FMS | 61 | COMT haplotype | Over-representation of LL variant (low activity). Similar to migraine and TMD |
| Offenbaecher and colleagues [8] | 1999 | 62 FMS | 110 | 5-HTT | One positive for over-representative SS genotype, one negative study. Suggestion that any association might be related to comorbid psychology |
| Gürsoy [9] | 2002 | 53 FMS | 60 mentally healthy | 5-HTT | Linkage to HLA |
| Yunus and colleagues [4] | 1999 | 40 multicase families | HLA | | |
| Buskila and colleagues [10] | 2004 | | | Dopamine D4 receptor polymorphism | Decrease in the frequency of the seven-repeat allele in exon III of the D4 receptor gene associated with fibromyalgia. Finding associated with low novelty-seeking personality |

COMT, catecholamine o-methyl transferase; FMS, fibromyalgia syndrome; 5-HT2A, serotonergic 5-hydroxytryptamine 2A receptor (T/T phenotype); 5-HTT, serotonin transporter; TMD, temporomandibular disorder.
The discrepancies between studies could either be because the therapies did not improve tenderness or because tender points are not a good measure of tenderness. Both factors are likely to play a role since, in certain studies where multiple measures of the pain threshold were used, tender point counts did not significantly improve whereas other measures did [21,22]. Moreover, other studies have shown that tender points are not a pure measure of tenderness. For example, there is a strong correlation between tender point counts and measures of distress in population-based studies [23]. Tender points have also been demonstrated to be biased by cognitive and emotional aspects of pain perception, whereas other measures of tenderness are much less so (see below) [24]. Improvements in tender point counts in some previous FM trials therefore possibly occurred because of improvements in distress, rather than because of inherent improvements in pressure pain threshold. Finally, tender points are often not continuously distributed in samples; rather, most people have either very few or nearly 18 tender points. As such, many investigators do not feel that tender point counts are useful to assess tenderness, and have instead turned to psychophysically and statistically superior measures.

Pressure pain thresholds
Directly measuring pressure pain thresholds is an alternative method of documenting tenderness. Devices that measure pressure pain thresholds have been used to demonstrate a left-shift and lowered pressure pain thresholds in patients with FM compared with control individuals, and this finding is noted anywhere in the body, both at tender points and in areas previously considered control points (Table 2). These findings suggest to many investigators that the term control points should be abandoned, or replaced by a term such as high-threshold tender point, since FM patients are just as tender in these regions relative to healthy control individuals.

Many of these studies initially used commercial devices or dolorimeters to deliver continuously increasing pressure via blunt probes. These measures were found to be sensitive to psychophysical and psychological biases, however, slightly similar to tender point counts using digital palpation (reviewed in [25]). For instance, the rate of increase of stimulus pressure, controlled by the operator, and patient distress were both shown to influence the pain threshold [24,26]. To minimize the bias, more sophisticated paradigms using random delivery of pressures have been developed and investigated [27,28] (Table 3). Random delivery may be less sensitive to certain influences, but it is not free of bias. For instance, in a study by Petzke and colleagues, FM patients reported higher pain during random delivery than during ascending – possibly due to a perceived lack of control [28].

A recent longitudinal study compared the three different evoked measures – tender point counts, the dolorimeter (ascending pressure paradigm), and the multiple random staircase (random pressure paradigm) – with clinical reports of pain improvement [21]. Although both clinical pain measures improved during the course of the study involving acupuncture, only one of the evoked measures – the multiple random staircase measure, which presented stimuli to individuals in an unpredictable fashion – improved after treatment. These results suggest that, of the different methods, the random stimuli paradigm may be more likely to systematically change over time. Interpretation of the results is nonetheless limited and will need to be reproduced and examined using other treatment modalities.

Heat, cold, and electrical stimuli
In addition to the heightened sensitivity to pressure noted in FM, other types of painful stimuli also are judged more painful by these patients. A decreased heat pain threshold in FM patients as compared with control individuals has been shown by multiple groups [28-30] (Table 4). A reduced cold pain threshold has been reported by one group in two different studies [30,31]. Sensitivity to warmth and the ability to detect electrical stimuli do not appear to be discriminative measures at this time.

Diminished diffuse noxious inhibitory control
In the process of understanding altered evoked pain sensitivity present in FM, evaluation of the intrinsic analgesic systems has uncovered another potential biomarker: diminished diffuse noxious inhibitory control (DNIC). DNIC testing in both animals and humans involves testing the pain threshold at baseline, and then administering an acutely painful stimulus that leads to a systemic analgesic effect, presumably by activating endogenous analgesic systems.

Several studies by different groups, using different conditioning stimuli (the acute noxious stimulus) and test stimuli (the stimulus used to measure pain threshold at baseline and following the acute, noxious stimulus), have indicated a deficiency of DNIC in individuals with FM. Diminished DNIC was observed in four cross-sectional studies by different groups that used variable test and conditioning stimuli [31,32-34] (Table 5). Diminished DNIC has also been noted in other types of chronic pain; that is, temporomandibular disorder and hip osteoarthritis [35,36]. The normalization of DNIC after hip osteoarthritis surgery suggests it may be an objective measure of chronic pain that can change over time with treatment [36].

Functional neural imaging
Functional neural imaging enables investigators to visualize how the brain processes the sensory experience of pain. The primary modes of functional imaging that have been used in FM include functional magnetic resonance imaging (fMRI), single-photon emission computed tomography (SPECT), and positron emission tomography.

fMRI studies evaluating pain processing have the strongest current evidence of the functional imaging studies, because
Table 2

Pressure pain thresholds in fibromyalgia

| Reference                          | Year of study | Number of FM patients | Number of control individuals | QST            | QST method | Findings                                                                 |
|-----------------------------------|---------------|-----------------------|-------------------------------|----------------|------------|--------------------------------------------------------------------------|
| Staud and colleagues [102]        | 2005          | 11                    | 12                            | PPT: affected and CP | ASC        | Decreased PPT (opposite of HC) after exercise                            |
| Sandberg and colleagues [103]     | 2005          | 19                    | 12                            | PPT: TP         | ASC        | FM, TM with decreased PPT                                               |
| Montoya and colleagues [104]      | 2005          | 12                    | 12                            | PPT, ERP        | ASC        | No difference (trend toward FM with decreased PPT). HC with decreased PPTs with repeat stimuli in one session. Decreased PPT for left hand versus right hand. FM decreased PPT in second assessment period (after EEG) |
| Laursen and colleagues [105]      | 2005          | 10 FM/whiplash, 10 RA, 10 CLBP, 10 endometriosis | 41                            | PPT: TP and CP  | ASC        | FM/whiplash, RA, endometriosis, CLBP with decreased PPT. Correlation between pressure hyperalgesia at lowest PPT sites and physical function impairment and mental health found |
| Landis and colleagues [51]        | 2004          | 37                    | 30                            | PPT: TP and CP  | ASC        | FM women with decreased PPT, PPT correlated with sleep spindle incidence and duration |
| Landis and colleagues [106]       | 2004          | 33                    | 37                            | PPT: TP         | ASC        | FM women with decreased PPT                                             |
| Maquet and colleagues [107]       | 2004          | 20                    | 50 females, 50 males          | PPT: TP         | ASC        | HC with decreased intraindividual variation (FM w/24%). HC females with decreased PPT compared with HC males. FM with decreased PPT compared with HC females. No difference between dominant and nondominant hands. PPT reproducibility and discrimination optimal at gluteal and knee |
| Geisser and colleagues [108]      | 2003          | 20                    | 20                            | PPT: TP and CP  | ASC        | FM with decreased PPT (more statistically significant than HPT). Catastrophizing correlated with decreased PPT. Depression associated with increased PPT |
| Yoldas and colleagues [47]        | 2003          | 11                    | 10                            | PPT and ERP     | ASC        | FM reduced P300 amplitude, correlated well with PPT                      |
| Embreg and colleagues [109]       | 2003          | 18                    | n/a                           | PP: over masseter | ASC        | No difference (trend toward decreased PPT after antagonist)             |
| Carli and colleagues [110]        | 2002          | 145 (FM, CFS, WP, MPTE, MP) | 22                            | PPT: CP and TP, HPT, CPT, cold pressor test, ischemic tourniquet test | ASC        | FM with decreased PPT (CFS, MPTE), HPT (CFS), cold pressor test (CFS), ischemic tourniquet test (CFS, MPTE, WP, MP) than HC |
| Hedenberg- Magnusson and colleagues [111] | 2002          | 18                    | 15 masseter myalgia           | PPT: over masseter | ASC        | Decreased PPT after treatment in both groups. Correlated with symptoms |
| Embreg and colleagues [112]       | 2000          | 12                    | 12 HC, 12 RA                  | PPT: masseter    | ASC        | FM with decreased PPT                                                    |
| Graven-Nielsen and colleagues [113] | 2000          | 15 FM ketamine responders | Placebo                       | EPT, PPT: TA muscle, PPT and pain tolerance: 3 TPs | ASC        | Increased PPT at TA muscle, pain pressure tolerance after ketamine compared with placebo. Noted improvement in symptoms |
| Embreg and colleagues [114]       | 2000          | 12                    | 12                            | PPT             | ASC        | FM with no significant increase in pain or decrease in PPT. HC with increased pain and decrease in PPT after infusion |
| Embreg and colleagues [115]       | 1999          | 18                    | 10 HC, 17 local myalgia       | PPT, pain tolerance: masseter | ASC        | FM with decreased PPT associated with higher fraction of masseter to serum serotonin levels |

Continued overleaf
they corroborate this left-shift in stimulus–response function (that is, hyperalgesia/allodynia) noted in FM. Specifically, several areas of the brain consistently show greater activation in FM patients than in control individuals given the same objective stimulus intensity – especially the secondary somatosensory cortex, insula and the anterior cingulate cortex. These findings have been noted in five cross-sectional studies by two different groups, using both pressure and heat stimuli [37,38] (Table 6). In the study by Giesecke and colleagues, the clinical pain intensity corresponded with an increase in the evoked regional cerebral blood flow [37]. The resting regional cerebral blood flow was evaluated by a third group in a longitudinal study using fMRI, and showed change after drug treatment [39]. These studies have also been useful in identifying differences in pain processing in individuals with and without psychological comorbidities, showing for example that depression does not seem to be influencing the magnitude of neuronal activation in sensory pain regions such as the secondary somatosensory cortex, whereas cognitive factors such as catastrophizing did influence the sensory intensity of pain [37,40].

Positron emission tomography imaging in FM has been reported in only a few studies with inconclusive results. The only positive study is a recent one showing there may be altered dopaminergic activity in FM [41].

SPECT imaging has been studied in four cross-sectional studies by different groups that consistently found reduced regional cerebral blood flow in the right thalamus of patients with FM (three of the four studies) [42-45]. No correlation between symptoms and findings were noted in the SPECT studies.

The consistent abnormalities seen in fMRI and SPECT studies suggest either of these methods might be useful to use as a biomarker, but longitudinal studies showing that improvements in symptoms coincide with normalization of functional imaging findings would be necessary to establish this role. The advantages of fMRI imaging over positron emission tomography and SPECT include the less invasive nature and the higher temporal and spatial resolutions of fMRI. Disadvantages of fMRI include the cost and prac-

---

Table 2
Continued

| Reference                      | Year of study | Number of FM patients | Number of control individuals | QST method | Findings                                      |
|--------------------------------|---------------|-----------------------|--------------------------------|------------|----------------------------------------------|
| Kosek and Hansen [30]         | 1997          | 10                    | 10                             | PPT        | ASC FM decreased PPT                         |
| Kosek and colleagues [31]     | 1996          | 10                    | 10                             | PPT        | ASC FM decreased PPT                         |
| McDermid and colleagues [116] | 1996          | 20                    | 20 HC, 20 RA                   | PPT: TP and CP | ASC FM decreased PT compared with RA, HC, RA decreased PT compared with HC |
| Kosek and colleagues [117]    | 1995          | 16                    | n/a                            | PPT at cream site | ASC No difference in PPT after EMLA cream |
| Tunks and colleagues [118]    | 1995          | 6                     | 6 myofascial pain controls, 6 HC | PPT: TP and CP | ASC FM and myofascial pain was discriminated from HC by dolorimetry and palpation |
| Wolfe and colleagues [119]    | 1995          | 391                   | n/a                            | TPC, dolorimetry | ASC PPT and TPC correlate with symptoms, but TPC correlates better |
| Gibson and colleagues [29]    | 1994          | 10                    | 10                             | PPT: TP and CP | ASC FM decreased PPT at CT and TP, but data not clearly shown |
| Lautenbacher and colleagues [120] | 1994      | 26                    | 26                             | PPT: CP and TP | ASC FM decreased PPT                         |
| Granges and Littlejohn [121]  | 1993          | 60                    | 60                             | PPT: TP and CP | ASC FM decreased HPT, PPT, CPT in CP and TP |
| Lautenschlager and colleagues [122] | 1991      | 47                    | n/a                            | PPT: TP and CP | ASC Body diagram correlated better with dolorimetric findings than visual analog scale |

ASC, ascending; CFS, chronic fatigue syndrome; CLBP, chronic low back pain; CP, control point; CPT, cold pain threshold; CT, cold perception threshold; EEG, electroencephalography; EMLA, local anesthetic cream; EPT, electrical pain threshold; ERP, event-related potential; FM, fibromyalgia; HC, healthy control individuals; HPT, heat pain threshold; MP, diffuse multiregional pain; MPTE, multiregional pain associated with at least 11 tender points; n/a, not applicable; PPT, pain pressure thresholds; QST, quantitative sensory testing; RA, rheumatoid arthritis; TA, tibialis anterior; TM, temporal mandibular disorder; TP, tender point; TPC, tender point count; WP, widespread pain.
ticability as well as the inability to perform receptor–ligand studies that are possible with positron emission tomography and SPECT.

**Event-related potentials**

Cerebral potentials evoked by noninvasive stimulation provide a unique opportunity to investigate the functional integrity and magnitude of brain processing pathways. Expressing the ability of the human brain to discriminate, classify, and memorize the significance of exogenous stimuli, event-related potentials (ERPs) have been used as a marker of cognitive function in patients with psychiatric and neurological disorders. The electrical waveforms generated can be divided into late and early components, and the waveforms are designated by their polarity (P-positive, N-negative) and latency (timing of peak) after stimulus onset. Additionally, the amplitude – the size of the voltage difference between the component peak and a prestimulus baseline – is also quantified. Auditory, somatosensory, and visual ERPs have been evaluated in patients with FM in a few studies.

Among the ERPs evaluated to date, the P300 potential (most commonly generated by an auditory consciously attended stimuli) appears to be the most promising to differentiate FM patients from control individuals. The P300 wave is a late cortical neuropsychological event, the latency of which reflects the information processing speed and the amplitude of which expresses memory functions. A reduced P300 amplitude during an auditory discriminated-task paradigm has been significantly noted in FM patients as compared with control individuals in three cross-sectional studies by two different groups [46-48] (Table 7). All three studies also evaluated the P300 latency, but only the largest study by Alanoglu and colleagues noted an increase in P300 latency, a finding that may have not been found in the prior studies due to lack of power [46]. In the one of these three studies by Ozgocmen and colleagues that performed ERPs before and after treatment, 8 weeks of sertraline treatment led to an increase in the P300 magnitude [48].

These studies generally failed to show an association between the ERP findings and symptom severity, although
Table 4

Heat pain threshold, cold pain threshold, and electrical stimuli in fibromyalgia

| Reference | Year of study | Number of FM patients | Number of control individuals | QST | QST method | Findings |
|-----------|---------------|-----------------------|------------------------------|-----|------------|----------|
| Petzke and colleagues [28] | 2003 | 43 | 28 | HPT, suprathreshold | ASC and RAN | FM decreased HPT, suprathreshold. Pain ratings from RAN were consistently higher than ASC, possibly due to perceived lack of perceived control |
| Gibson and colleagues [29] | 1994 | 10 | 10 | WT and HPT | ASC and RAN | FM decreased HPT, no difference in WT |
| Staud and colleagues [102] | 2005 | 11 | 12 | Suprathreshold: affected and CP | ASC | Increased thermal pain ratings after exercise (opposite of HC) |
| Geisser and colleagues [108] | 2003 | 20 | 20 | HPT, WT | ASC | FM with decreased HPT. Higher intensity and unpleasantness for non-noxious stimuli |
| Kosek and Hansson [30] | 1997 | 10 | 10 | CT, WT, CPT, HPT | ASC | FM decreased CT in forearm. FM decreased CPT and HPT. No difference in WT |
| Lautenbacher and Rollman [34] | 1997 | 25 | 26 | HPT | ASC | FM had decreased HPT |
| Kosek and colleagues [31] | 1996 | 10 | 10 | CT, WT, CPT, HPT | ASC | FM decreased HPT, CPT. FM had decreased WT only at TP |
| Lorenz and colleagues [128] | 1996 | 10 | 10 | HPT | ASC | FM decreased HPT |
| Lautenbacher and colleagues [120] | 1994 | 26 | 26 | HPT | ASC | FM decreased HPT, no difference in WT |
| Lautenbacher and Rollman [34] | 1997 | 25 | 26 | Electrical | ASC | No difference in electrical detection/PT |
| Lautenbacher and colleagues [120] | 1994 | 26 | 26 | Electrical – CP and TP | ASC | FM decreased electrocutaneous only at TP, not control points |
| Arroyo and Cohen [129] | 1993 | 10 | 10 | Electrical detection, suprathreshold | ASC | No difference in electrical detection, FM decreased electrical tolerance |

ASC, ascending; CP, control point; CPT, cold pain threshold; CT, cold perception threshold; FM, fibromyalgia; HC, healthy control individuals; HPT, heat pain threshold; PT, pain threshold; QST, quantitative sensory testing; RAN, random; TP, tender point; WT, warmth perception threshold.

Table 5

Diffuse noxious inhibitory controls (DNIC) in fibromyalgia (FM)

| Reference | Year of study | Number of FM patients | Number of control individuals | Test stimuli (noxious stimuli) | Heterotopic conditioning noxious stimuli | Findings |
|-----------|---------------|-----------------------|------------------------------|-------------------------------|-----------------------------------------|----------|
| Julien and colleagues [32] | 2005 | 30 | 30 HC, 30 CLBP | Water bath, cold, noxious | Water bath, cold, noxious | Diminished DNIC in FM patients, not CLBP |
| Staud and colleagues [33] | 2003 | 11 | 22 females, 11 males | Wind up | Water bath, heat, noxious | Diminished DNIC in female HC and female FM patients |
| Kosek and Hansson [30] | 1997 | 10 | 10 | CT, WT, HPT, CPT | Tourniquet | Diminished DNIC in FM patients |
| Lautenbacher and Rollman [34] | 1997 | 25 | 26 | Electrical pain threshold | Thermode tonic cold thermal, noxious and non-noxious | Diminished DNIC in FM patients |

CLBP, chronic low back pain; CT, cold perception threshold; CPT, cold pain threshold; HC, healthy control individuals; HPT, heat pain threshold; WT, warmth perception threshold.
Table 6

Neural imaging in fibromyalgia (FM)

| Reference                      | Year of study | Number of FM patients | Number of control individuals | Neural imaging | Description                          | QST | Findings                                                                                                                                                                                                 |
|-------------------------------|---------------|-----------------------|-------------------------------|----------------|---------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Giesecke and colleagues [37]  | 2005          | 7                     | 7 MDD/FM, 7 HC                | fMRI           | QST evoked rCBF association to depression | Pressure pain rCBF, MRS | Clinical pain intensity – associated with increased rCBF of insula bilaterally, contralateral ACC, prefrontal cortex. Symptoms of depression – not associated with increased rCBF of SI, SII, associated amygdala and contralateral anterior insula. |
| Gracely and colleagues [40]   | 2004          | 15 high catastrophizers | 14 low catastrophizers       | fMRI           | QST evoked rCBF association to catastrophizing | Pressure pain rCBF, MRS | Both low and high with increased rCBF in contralateral insula, SI, SII, inferior parietal lobule and thalamus, ipsilateral S1, cerebellum, posterior cingulate gyrus, and superior and inferior frontal gyrus. High catastrophizers with unique activation in contralateral anterior ACC, contralateral ipsilateral lentiform. |
| Giesecke and colleagues [124] | 2004          | 16                    | 11 HC, 11 CLBP               | fMRI           | QST evoked rCBF                       | Pressure pain rCBF, MRS | In CLBP and FM patients, QST (equal pressure) increased rCBF of contralateral SI and SII, inferior parietal lobule, cerebellum, and ipsilateral SII. In HC, QST (equal pressure) activation of contralateral SII. Equal evoked equal pain associated with similar activation. |
| Koepepe and colleagues [39]   | 2004          | ?                     | None                          | fMRI           | Injection of 5-HT-3 receptor antagonist (topisetron) rCBF | n/a | In FM patients, topisetron treatment reduced rCBF of SI, contralateral posterior insula, ACC. |
| Cook and colleagues [38]      | 2004          | 9                     | 9 HC                          | fMRI           | QST evoked activation of rCBF         | Nonpainful and painful heat, 47°C | In FM, nonpainful heat increased rCBF in prefrontal, supplemental motor, insular, and ACC as compared with HC. In FM patients, painfult heat increased activity in contralateral insular cortex as compared with HC. |
| Gracely and colleagues [126]  | 2002          | 16                    | 16 HC                         | fMRI           | QST evoked activation of rCBF         | Pressure pain rCBF, MRS, neutral site | Common areas of evoked equal pain increased rCBF including contralateral SI, inferior parietal lobule, SI, superior temporal gyrus (STG), insula, putamen, and ipsilateral cerebellum. Decreased rCBF in ipsilateral SI. In HC, QST (equal pressure) activated ipsilateral STG and precentral gyrus. |
| Yunus and colleagues [130]    | 2004          | 12                    | 7 HC                          | PET            | Resting rCBF                          | n/a | No difference                                                                                                                                                                                            |
| Chang and colleagues [131]    | 2003          | 10 IBS + FM            | 10 IBS                        | PET            | QST evoked activation of rCBF         | Noxious visceral and somatic pressure | In IBS patients, noxious visceral stimuli evoked increased rCBF increase in middle subregion of the ACC. In IBS + FM patients, somatic stimuli evoked greater rCBF in middle subregion of the ACC extending to ACC and the thalamus. |

Continued overleaf
there was an association noted with the total myalgic score. Although the change in the P300 potential after sertraline treatment was attractive, the authors agreed that – given the corresponding significant clinical improvement in pain, fatigue, or depression – the mechanism for the change remained unclear, and they acknowledged it may represent regression to the mean. Larger studies by different groups with an attention to standardizing methods are essential prior to mainstream use of this marker.

In contrast to auditory potentials, there are few and varied studies evaluating somatosensory and visual ERPs. The assorted protocols used in the studies investigating somatosensory and visual ERPs may have contributed to the lack of consistently demonstrated differences in FM and normal individuals. The lack of an established standardized methodology makes direct comparison difficult and may limit the evidence of reproducibility.

**Sleep and activity**

In addition to pain, other symptoms very commonly seen in FM include disturbed sleep and poor function. Sleep logs and polysomnography have consistently confirmed patient reports of hypersomnolence [49,50]. Using polysomnography, investigators have correlated hypersomnolence with poor sleep quality by demonstration of fewer sleep spindles, an increase in the cyclic alternating pattern rate, or poor sleep efficiency [51-53]. Sleep abnormalities are rarely shown to correlate with symptoms in FM, however, and many investigators anecdotally feel as though even identifying and treating specific sleep disorders often seen in FM patients (for example, obstructive sleep apnea, upper airway resis-

---

**Table 6**

(Continued)

| Reference          | Year of study | Number of FM patients | Number of control individuals | Neural imaging | Description | QST | Findings                                                                 |
|--------------------|---------------|-----------------------|-------------------------------|----------------|-------------|-----|--------------------------------------------------------------------------|
| Wik and colleagues [132] | 2006          | 8                     | None                          | PET            | QST evoked activation of rCBF | Acute pain | In FM patients, frontal and parietal cortical activation during acute pain compared with rest (as expected). Reduced rCBF in retrosplenial cortex (evaluative processing) |
| Wood and colleagues [41] | 2007          | 11                    | 11 HC                         | PET            | QST evoked binding of D2/D3 ligand | Nonpainful and painful saline injection | In FM patients, lack of dopamine release in basal ganglia compared with HC during painful stimuli. In HC, amount of dopamine release correlated with amount of perceived pain; in FM patients, no such correlation observed |
| Adiguzel and colleagues [42] | 2004          | 14                    | None                          | SPECT          | Amitriptyline (3 months) resting rCBF | n/a | Increased rCBF in bilateral hemithalami after amitriptyline. No correlation between symptoms and findings |
| Gur and colleagues [45] | 2002          | 19                    | 20 HC                         | SPECT          | Resting rCBF                      | n/a | Increased rCBF in caudate nucleus. FM patients with less depression had increased uptake in pons |
| Kwiatek and colleagues [43] | 2000          | 17                    | 22 HC                         | SPECT          | Resting rCBF                      | n/a | Reduced rCBF in right thalamus and potine tegmentum, no reduction in left thalamus, or caudate nucleus. No correlation between symptoms and findings |
| Mountz and colleagues [44] | 1995          | 10                    | 7 HC                          | SPECT          | Resting rCBF                      | n/a | Reduced rCBF in bilateral hemithalami and caudate nucleus correlated with low pain threshold. No correlation between symptoms and findings |

ACC, anterior cingulate cortex; CLBP, chronic low back pain; fMRI, functional magnetic resonance imaging; HC, healthy control individuals; 5-HT-3, 5-hydroxytryptamine 3; IBS, irritable bowel syndrome; MDD, major depression disorder; MRS, multiple random staircase; n/a, not applicable; PET, positron emission tomography; QST, quantitative sensory testing; rCBF, regional cerebral blood flow; SI, somatosensory cortex I; SII, somatosensory cortex II; SPECT, single-photon emission computed tomography.
Actigraphy

A method of motion assessment that infers sleep and wakefulness from the presence of limb movements, actigraphy is increasingly being used as a surrogate marker for both sleep and activity. The actigraph typically combines a movement detector and memory storage on a watch-like device. The device can be worn on the wrist or the ankle continuously for long periods of time. Sleep-pattern measures available via actigraphy analyses include sleep latency, the wake time after sleep onset, and the total sleep time; sleep architecture cannot be measured, as with polysomnography. Compared with polysomnography, however, actigraphy is less expensive, less invasive, and more conducive to repeated measures, resulting in extensive use in intervention studies [54].

Actigraphy is being increasingly used in FM studies and appears promising, but has not yet proven adequately sensitive to stand alone in clinical evaluation or treatment trials [50,55,56]. As a measure of sleep quality there have been inconsistent actigraphy results, with one group noting increased levels of activity at night in FM (also noted in patients with major depression) [55] and another group noting no difference [50]. Edinger and colleagues used actigraphy as an outcome measure in an intervention trial comparing cognitive behavior therapy intervention with sleep hygiene and usual care in the treatment of insomnia [57]. Deriving an actigraphic improvement criterion, the investigators showed a greater number of patients receiving cognitive behavior therapy had clinically significant improvement in the total wake time compared with sleep hygiene therapy. No statistical difference between cognitive behavior therapy and usual care was able to be demonstrated, even though a statistical difference between the groups was shown using sleep log data in the same study.

As an objective measure of functional status, actigraphy might hold more promise as a surrogate outcome measure, because it allows the direct recording of activity levels, rather than relying on patient self-report [58]. Kop and colleagues demonstrated that although patients with FM have 36-Item Short Form health survey scores nearly two standard deviations below the population average, they have the same average activity level as a group of sedentary control individuals [58]. The FM patients had much lower peak activity levels, however, suggesting that the problems in function that FM patients report might be more due to an inability to rise to the intermittent demands of day-to-day life than due to overall reduced function.

Table 7

| Reference                     | Year of study | Number of FM patients | Number of control individuals | Evoked potential Paradigm | EP evaluated | Findings                                                                 |
|-------------------------------|--------------|-----------------------|-------------------------------|---------------------------|--------------|--------------------------------------------------------------------------|
| Alanoglu and colleagues [46]  | 2005         | 34                    | 22                            | Auditory                  | P300 wave    | FM reduced P300 amplitude and prolonged latency. No correlation between EP findings, pain scores, and quality of life measurements |
| Yoldas and colleagues [47]    | 2003         | 11                    | 10                            | Auditory                  | P300 wave    | FM reduced P300 amplitude, but no difference in potential latency. P300 latency negatively correlated with total myalgic scores and the control point scores. P300 amplitude correlated with PPT and total myalgic scores. No correlation in amplitude or latency with depression or anxiety. |
| Ozgocmen and colleagues [48]  | 2003         | 13                    | 10                            | Auditory                  | P300 wave    | FM reduced P300 amplitude, but no difference in potential latency at baseline. Sertraline treatment resulted in increase in potential amplitude by 8 weeks without change in latency. No correlation between EP findings, fatigue and pain scores, but correlated to total myalgic scores |

EP, evoked potential; PPT, pain pressure thresholds.
Stress–response systems and sex hormones

The theoretical link between stress–response systems and symptom expression is supported by studies demonstrating alterations of the hypothalamic–pituitary–adrenal axis and the autonomic nervous system in FM. Probing different aspects of the stress systems is underway to uncover objective ways to identify persons at risk or to identify reproducible abnormalities. One group clearly with increased susceptibility is women. Investigators hypothesize a potential effect of sex hormones on the stress response to partly explain the female predominance seen in FM, but this connection has not yet been specifically examined in FM patients [59].

Hypothalamic–pituitary–adrenal axis

In basal and diurnal cortisol studies, the most consistently found measure is a flattened diurnal plasma cortisol level with an elevated trough, found in three of four cross-sectional studies by two out of three groups [60-62] (Additional file 1). Studies evaluating basal plasma cortisol levels, salivary basal and diurnal cortisol levels, and urinary cortisol levels have shown inconsistent results, but they generally demonstrate normal to reduced basal levels. Since atypical depression can show a reduced cortisol level, biopsychosocial factors that influence cortisol levels may be contributing to the inconsistent results currently found in the literature [63]. These factors need to be better elucidated and accounted for in future studies. Nonetheless, a flattened diurnal cortisol level is a promising objective measure.

Evaluation of other components of the hypothalamic–pituitary–adrenal axis has been relatively unrevealing. Basal and diurnal adrenocorticotropic hormone shows no difference in FM patients versus healthy control individuals [62,64,65] (Additional file 1). Provocative hypothalamic–pituitary–adrenal studies utilizing the cosyntropin test have shown inconsistent results [62,66-68] (Additional file 2).

Results of the dexamethasone suppression test have been reported in a number of studies by different groups, and the results reveal normal to high levels of cortisol following infusion of the corticosteroid [60,64,66,69,70] (Additional file 3). Depression also typically follows a pattern of resistance to the dexamethasone test, and therefore is a confounding factor in a large number of these evaluations.

Studies have also been completed to assess the cortisol response to exogenous corticotropin-releasing hormone or endogenous activators of corticotropin-releasing hormone (that is, hypoglycemia, IL-6) in FM. Investigators found normal to reduced cortisol levels in patients with FM after an increase in corticotropin-releasing hormone, but these results were not reproduced in other similar studies. Further investigation taking into account psychological factors as well as doses of different drugs will be prudent.

Autonomic reactivity

Tilt table testing and heart rate variability have been evaluated in patients with FM. The consistent and reproducible finding of lower heart rate variability in FM patients compared with control individuals (in three cross-sectional studies by two different groups) makes it a more useful measure than tilt table testing [71-73]. An abnormal drop in blood pressure or an excessive rate of syncope during tilt table testing has been noted in two out of three cross-sectional studies completed by three different groups [74-76]. One study noted no difference in normal individuals and control individuals using univariate analysis [76]. Moreover, recent findings also suggest that aberrations in heart rate variability may predispose to fibromyalgia symptoms [77,78], possibly identifying patients at risk.

Sex hormones

FM syndrome is more prevalent in women than in men, suggesting a role of sex hormones in the pathophysiology of FM [79]. To date, two studies have failed to show an association between sex hormones and pain sensitivity [79,80]. The reason for a female predominance in FM is complex and warrants further investigation.

Serologic and biochemical abnormalities

Physicians from multiple disciplines have used simple blood tests to diagnose and evaluate treatment for various diseases. Scientists have similarly evaluated a number of compounds in the serum and cerebrospinal fluid of patients with FM to find a comparable marker of disease or disease activity. Despite the effort to find easily accessible measures, no clinically suitable tests have yet been appropriately validated for FM.

Autoantibodies

The search for representative autoantibodies is a predictable step for a disease like FM, often evaluated by rheumatologists and coexisting with autoimmune diseases. Antiserotonin antibody, antianganglioside antibody, and anti-phospholipid antibody have been shown to be different in FM patients and control individuals, but the applicability of these findings is not yet clear [81] (Table 9). Antiserotonin antibody has been shown to be increased in FM in three cross-sectional studies by two different groups [81-83]. Antianganglioside antibody and antiphospholipid antibody have been shown to be increased in FM in three cross-sectional studies by two different groups [81-83]. Antiserotonin antibody and antithromboplastin antibody [83], antipolymer antibody [84], and anti-68/48 kDa and anti-45kDa [85] have each been shown to be increased in FM in two cross-sectional studies by the same group [81,82]. A different group evaluating antianganglioside antibody in a third cross-sectional study was unable to reproduce the results [83]. Antithromboplastin antibody [83], antipolymer antibody [84], and anti-68/48 kDa and anti-45kDa [85] have each been evaluated in one cross-sectional study and have shown increased levels in FM. A review of the literature demonstrates that antinuclear antibodies, antithyroid antibodies, antisilicone antibodies, and antiglumric acid decarboxylase are not informative in FM.
## Table 8

**Basal and diurnal cortisol and fibromyalgia (FM)**

| Reference                          | Year of study | Number of FM patients | Number of control individuals | Measured (plasma) | Findings                                                                                                                                 |
|-----------------------------------|---------------|-----------------------|-------------------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| McCain and Tilbe [60]             | 1989          | 20                    | 20 RA                         | Plasma cortisol   | Normal peak, elevated trough, flattened diurnal compared to RA                                                                            |
| Crofford and colleagues [133]     | 1994          | 7                     | 7                             | Plasma cortisol   | Normal peak, elevated trough, flattened diurnal                                                                                           |
| Crofford and colleagues [61]      | 2004          | 13                    | 12 FMS + CFS, 15 CFS          | Plasma cortisol   | Delay in rate of decline in FM, elevated cortisol in late period in FM, flattened diurnal, lower O/N cortisol in CFS                     |
| Adler and colleagues [62]         | 1999          | 15                    | 13                            | Plasma cortisol – total and free | Normal, normal diurnal                                                                                                                     |
| Korszun and colleagues [134]      | 1999          | 9                     | 9 HC, 8 CFS                   | Plasma cortisol   | Normal                                                                                                                                  |
| Malt and colleagues [135]         | 2002          | 22                    | 13                            | Plasma cortisol   | Normal                                                                                                                                  |
| Valkeinen and colleagues [136]    | 2005          | 13 (60 years old)     | 13 (59 years old)             | Plasma cortisol   | Normal                                                                                                                                  |
| Gur and colleagues [64]           | 1993          | 10                    | 10                            | Plasma cortisol   | Normal                                                                                                                                  |
| Gur and colleagues [137]          | 2004          | 63 (<35 years old)    | 38 (<35 years old)            | Plasma cortisol   | Reduced                                                                                                                                  |
| Gur and colleagues [63]           | 2004          | 68                    | 46 HC, 62 CFS                 | Plasma cortisol   | Reduced in FM with high BDI scores (>17), not in those with low BDI. Reduced in CFS                                                       |
| Grieb and colleagues [66]         | 1998          | 40                    | 14 HC, 28 CLBP                | Plasma cortisol   | Reduced                                                                                                                                  |
| Lentjes and colleagues [138]      | 1997          | 40                    | 14 HC, 28 CLBP                | Plasma cortisol – total and free | Reduced total cortisol in FM only, Normal free cortisol in FM, CLBP                                                                         |
| Riedel and colleagues [65]        | 1998          | 16                    | 17                            | Plasma cortisol   | Elevated                                                                                                                                |
| Catley and colleagues [139]       | 2000          | 21                    | 22 HC, 18 RA                  | Salivary cortisol | Elevated, normal diurnal                                                                                                                 |
| McGee and colleagues [140]        | 2005          | 20                    | 16                            | Salivary cortisol | Normal, normal diurnal strong relationship between current pain symptoms and cortisol levels at waking and 1 hour after waking. No relationship between fatigue and stress |
| Weissbecker and colleagues [141]  | 2006          | 85                    | n/a                           | Salivary cortisol | Flattened diurnal, greater cortisol responses to awakening in FM with history psychological, physical abuse                               |
| Dedert and colleagues [142]       | 2004          | 91                    | n/a                           | Salivary cortisol | Flattened diurnal on those with low religiosity                                                                                            |
| Sephton and colleagues [143]      | 2003          | 50                    | n/a                           | Salivary cortisol | Higher log-transformed mean salivary cortisols associated with better memory                                                              |
| Adler and colleagues [62]         | 1999          | 15                    | 13                            | 24-hour urinary cortisol | Normal                                                                                                                                  |
| Maes and colleagues [144]         | 1998          | ?                     | PTSD, depression              | 24-hour urinary cortisol | Normal                                                                                                                                  |
| Torpy and colleagues [145]        | 2000          | 13                    | 8                             | 24-hour urinary cortisol | Normal (trend toward reduced)                                                                                                              |
| Crofford and colleagues [133]     | 1994          | 12                    | 10                            | 24-hour urinary cortisol | Reduced (no difference between depressed and non depressed)                                                                                 |
| Lentjes and colleagues [138]      | 1997          | 40                    | 14 HC, 28 CLBP                | 24-hour urinary cortisol | Reduced in FM and CLBP                                                                                                                    |
| Griep and colleagues [66]         | 1998          | 40                    | 14 HC, 28 CLBP                | 24-hour urinary cortisol | Reduced                                                                                                                                  |

BDI, Beck Depression Inventory; CFS, chronic fatigue syndrome; CLBP, chronic low back pain; FMS, fibromyalgia syndrome; HC, healthy control individuals; PTSD, post-traumatic stress disorder; RA, rheumatoid arthritis.
The nonspecific increase in antibodies to a number of antigens may be a nonspecific finding that arises from a subtle shift in immune function in this spectrum of illness. In the closely related chronic fatigue syndrome, investigators have noted a shift from a T1 to a T2 immune response, which would be expected to lead to increased production of nonspecific antibodies. Any antibody or autoantibody proposed as either a diagnostic test for FM or a biomarker of FM must therefore be carefully tested using various control individuals to ensure its authenticity.

Neuropeptides
Substance P is a neuropeptide released in spinal fluid when axons are stimulated. Four different cross-sectional studies by various groups in FM patients noted an elevation of substance P in cerebrospinal fluid [86-89]. In contrast, a normal substance P level has been noted in the cerebrospinal fluid of patients with chronic fatigue syndrome [90]. Although these results appear promising, elevated substance P is not specific for FM but rather has been shown to occur in other pain states such as chronic, daily headaches and chronic neck or shoulder pain associated with whiplash injury [91,92]. A high level of substance P therefore seems to be a biological marker of the presence of chronic pain.

Nerve growth factor and calcitonin gene-related peptide are additional neuropeptides that have been evaluated in FM. Nerve growth factor was shown in one study to have increased levels in FM and not in FM/rheumatoid arthritis overlap, therefore presenting inconclusive results [93]. Cerebrospinal fluid and serum calcitonin gene-related peptide have been studied and not found to be different in FM patients and control individuals [94,95].

Biochemicals and cytokines
The amino acid tryptophan and the cytokine IL-8 have both been shown to be different in patients compared with control individuals in a couple of studies, but neither have been evaluated in longitudinal studies [96-98]. A low tryptophan level has been found in two of three studies by three different groups [96,99,100]. IL-8 has been consistently demonstrated in three studies by two different groups [97,98,101]. Moreover, IL-8 has been shown to correlate with symptoms of FM and not to be associated with depressed FM [98]. Serum IL-6 was evaluated and found to be normal in FM patients [98,101].

Muscle abnormalities
Despite the interest and investigation for objective peripheral muscle abnormalities, the results have remained variable and have not yet been reproduced by different groups. Additionally, there is great heterogeneity in the methods evaluating for objective muscle abnormalities that render a complete review of the data beyond the scope of the present study. To dissect out possible useful objective measures, further investigations are necessary, preferably utilizing noninvasive procedures.
Conclusion
Except for psychophysical pain testing, no objective measure has been appropriately evaluated and shown to improve with improvements in clinical status in a longitudinal study, and thus to qualify as a biomarker (see Table 10 for summary). These tests are not, however, entirely objective. Of the objective tests, those that hold the most promise as biomarkers are probably tests that directly assess elements of neural function, such as functional neuroimaging, ERPs, and DNIC. An effort by different groups to systematically evaluate these measures in research trials to obtain useful, comparable results will be vital for ongoing progress in outcome research. There will be an ongoing need to identify biomarkers for future studies that have reproducibility and predictive value, practicability, and biological and temporal relevance in FM.

Additional files
The following Additional files for this article are available online:

Additional file 1 is an Excel file containing a table that presents studies of basal and diurnal adrenocorticotropic hormone and fibromyalgia. See http://arthritis-research.com/content/supplementary/ar2443-s1.xls

Additional file 2 is an Excel file containing a table that presents studies of the cosyntropin test and fibromyalgia.

Table 10
Summary of findings for objective markers

| Objective marker                        | Findings                                                                                                                                 |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Genetics                               | Polymorphisms in catecholamine \(\alpha\)-methyl transferase have been noted in some ethnic groups but not others; dopamine 4 receptor findings have not been replicated or refuted as compared with other polymorphisms |
| Tender point counts or index           | Multiple studies suggesting utility. The tender point count and the tender point index may be influenced by cognitive and emotional aspects of pain, and therefore may be biased |
| Pressure pain threshold                | Multiple studies suggesting utility. The pressure pain threshold may be influenced by cognitive and emotional aspects of pain, which may be minimized by utilizing a random pressure paradigm |
| Heat and cold pain threshold           | Consistently different in patients versus control individuals but not shown to be correlated with changes in clinical pain |
| Diminished diffuse noxious inhibitory controls | Four cross-sectional studies by different groups suggest utility. Needs further exploration with standardized methods, longitudinal studies |
| Functional neural imaging              | Multiple studies suggesting utility. May be influenced by cognitive aspects of pain. Longitudinal studies needed |
| Event-related potentials               | Reduced P300 amplitude has been noted in three cross-sectional studies by two different groups. Larger studies with standardized methods are necessary. Longitudinal studies needed |
| Sleep logs and polysomnography         | Confirm reports of hypersomnolence, but no changes are pathognomonic of or specific for fibromyalgia |
| Actigraphy                             | Inconsistent measure of sleep quality. Report suggesting utility in measuring functional status. Larger, longitudinal studies needed |
| Hypothalamic–pituitary–adrenal axis    | Flattened diurnal cortisol noted in three of four cross-sectional studies by two of three groups. Need to explore influence of biopsychosocial factors. Longitudinal studies needed |
| Autonomic reactivity                   | Lower heart rate variability noted in three cross-sectional studies by two different groups. May predispose to condition. Longitudinal studies needed |
| Autoantibodies                         | Antiserotonin antibody noted to be increased in three cross-sectional studies by two different groups. Stringent controls necessary prior to determining utility. Longitudinal studies needed |
| Neuropeptides                          | Substance P noted to be increased in cerebrospinal fluid in four cross-sectional studies by various groups. Potential nonspecific marker of chronic pain |
| Biochemical and cytokines              | Low tryptophan and elevated IL-8 noted. Longitudinal studies needed |
| Muscle abnormalities                   | No clear and reproducible abnormality. Additional studies with standardized methods needed |

This review is part of a series on Biology and therapy of fibromyalgia edited by Leslie Crofford.

Other articles in this series can be found at http://arthritis-research.com/articles/review-series.asp?series=ar_fibromyalgia
Competing interests

DD is a consultant for Forest Laboratories. LJC is a consultant for Pfizer, Wyeth, Lilly, and Allergan, and receives research grant support from Pfizer, Wyeth, Allergan, and Boehringer-Ingelheim. MS is a consultant to Allergan, Eli Lilly, Jazz Pharmaceuticals, Pfizer and Pierre Fabre Medicament, and is on the speaker bureaus of Eli Lilly, Grünenthal, Pfizer and Pierre Fabre Medicament. IJR is a consultant for Allergan and Grünenthal, has research grant support from Allergan, Schwartz, Grünenthal, Jazz Pharmaceuticals, and Forest Laboratories, and is on the speaker bureau for Jazz Pharmaceuticals, Pfizer, and Forest Laboratories. DJC is a consultant for Cypress Biosciences, Pfizer, Lilly, Forest Laboratories, Wyeth, Proctor and Gamble, and Takeda.

References

1. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB Stark LO, Keck PE Jr: Family study of fibromyalgia. Arthritis Rheum 2004, 50:944-952.
2. Yunus MB, Khan MA, Rawlings KK, Olson JM, Shah S: Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999, 26:408-412.
3. Bondy B, Spaeth M, Offenhaecker M, Glatzeder K, Stratz T, Schwarz M de Jonge S, Kruger M, Engel RR, Farber L, Pongratz DE, Ackenheil M: The T102C polymorphism of the 5-HT2A receptor gene in fibromyalgia syndrome. Pharmacogenomics 2007, 8:87-94.
4. Simms RW, Roy SH, Hrovat M, Andersen JJ, Skinar G, LePoole SR Zerbini CA, de Luca C, Jolesz F: Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum 1994, 37:794-800.
5. Bunkila D, Sassi-Putitti P, Abin JN: The genetics of fibromyalgia syndrome. Pharmacogenomics 2007, 8:87-94.
6. Yunus MB, Khan MA, Rawlings KK, Olson JM, Shah S: Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999, 26:408-412.
7. Bondy B, Spaeth M, Offenhaecker M, Glatzeder K, Stratz T, Schwarz M de Jonge S, Kruger M, Engel RR, Farber L, Pongratz DE, Ackenheil M: The T102C polymorphism of the 5-HT2A receptor gene in fibromyalgia syndrome. Pharmacogenomics 2007, 8:87-94.
36. Kosek E, Ordeberg G: Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 2004, 88:69-78.

37. Giesecke T, Gracely RH, Williams DA, Geisser M, Petzke F, Clauw DJ: The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005, 52:1577-1584.

38. Cook DB, Lange G, Cicone DS, Liu WC, Steffener J, Natelson BH: Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004, 31:364-378.

39. Koepp C, Schneider C, Thieme K, Mense S, Stratz T, Muller W, Flo H: The influence of the S-HT3 receptor antagonist troperidol on periodic breathing during sleep in patients affected by fibromyalgia syndrome. Scand J Rheumatol Suppl 2004, 119:24-27.

40. Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, Clauw DJ: Pain catastrophizing and neuralauditory event-related brain potentials among persons with fibromyalgia. Brain 2004, 127:835-843.

41. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakemrez A, Rabiner EA, Bushnell MC, Chizz BA: Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2003, 18:3578-3584.

42. Adiguzel O, Kaptanoglu E, Turgut B, Nacitarhan V: The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semi-quantitative SPECT. South Med J 2004, 97:851-855.

43. Kostek E, Bardeen L, Federman I, Jurell R, Chew J, Rowe C, Pile K: Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalamus. Arthritis Rheum 2004, 43:2829-2833.

44. Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, Stewart KE, Alarcon GS, Mountz JD: Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low hypothalamicadrenal hormone levels. Arthritis Rheum 1998, 38:926-938.

45. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ: Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002, 20:753-760.

46. Alanoglu E, Ozcetin O, Kosek E, Ozyurt B: Self-reported sleep quality and fatigue correlates with alterations in hypothalamicpituitaryadrenal axis in women with fibromyalgia. Sleep Med 2003, 4:89-93.

47. Veldas T, Ozogcmen S, Yildizhan H, Yigit Y, Eliv U, Ardigoclu O: Auditory p300 event-related potentials in fibromyalgia patients. Yonsei Med J 2000, 31:1374-1381.

48. Landis CA, Frey CA, Lentz MJ, Rothermel J, Buchwald D, Shaver JL: Self-reported sleep quality and fatigue correlates with alterations in hypothalamicpituitaryadrenal axis in women with fibromyalgia. Nurs Res 2003, 52:140-147.

49. Landis CA, Lentz MJ, Rothermel J, Buchwald D, Shaver JL: Decreased sleep spindles and spindle activity in middle age women with fibromyalgia. Arch Intern Med 2003, 163:2527-2535.

50. Long AC, Palermo TM, Manees AM: Brief report: using actigraphy to compare physical activity levels in adolescents with chronic pain and healthy adolescents. J Pediatr Psychol 2008, 33:660-665.

51. Edinger JD, Wohlgenuth WK, Krystal AD, Rice JR: Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. Arch Intern Med 2005, 65:294-303.

52. Kop WJ, Lyden A, Berlin AA, Ambrose K, Olsen C, Gracely RH, Williams DA, Clauw DJ: Ambulatory monitoring of physical activity and symptoms in fibromyalgia and chronic fatigue syndrome. Arthritis Rheum 2005, 52:294-303.

53. Kajantie E, Phillips DI: The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology 2006, 31:151-178.

54. McCain GA, Tibe KS: Diurnal hormone variation in fibromyalgia syndrome: a new marker of sleep alteration in patients with fibromyalgia syndrome/or chronic fatigue syndrome. Brain Behav Immun 2004, 18:314-325.

55. Adiger GL, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL: Reduced hypothalamicpituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. J Am Coll Endocrinol Metab 1999, 106:164-170.

56. Gur A, Cevik R, Nas K, Colpan L, Sarac S: Cortisol and hypothalamicpituitarygonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones. Arthritis Rheum 2004, 52:862-869.

57. Alioglu S, Ozceri A, Yildiz O, Alioglu A: Evaluation of dexamethasone suppression test in fibromyalgia patients with or without depression. Swiss Med Wkly 2003, 133:241-244.

58. Cohen H, Neumann L, Shore M, Amor C, Cassuto Y, Buskila D: Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability [see comments]. Semin Arthritis Rheum 2005, 34:217-227.

59. Cohen H, Neumann L, Kotler M, Buskila D: Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. Isr Med Assoc J 2001, 3:755-760.

60. Martinez-Lavin M, Lombard P, Rosas M, Soto ME: Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998, 41:1866-1871.

61. Bou-Holaigah I, Calkins H, Flynn JA, Tunin C, Chang HC, Kan JS, Rowe PC: Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 1997, 15:239-246.

62. Furlan R, Colombo S, Peruge F, Atzeni F, Daniel B, Barbic F, Porta A, Pace F, Malliani A, Sarzi-Puttini P: Abnormalities of cardio-
vascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol 2005, 32: 1787-1793.

76. Naschitz JE, Mussafia-Prielac R, Peck ER, Peck S, Naftali N, Storch S, Slobodin G, Elias N, Rosner I: Hyperventilation and amplified blood pressure response: is there a link? J Hum Hypertens 2005, 19:381-387.

77. McBeth J, Chiu YH, Silman AJ, Ray D, Morriss R, Dickens C, Ogden A, Macfarlane GJ: Hypothalamic-pituitary-adrenal stress axis function and the relationship with chronic widespread pain and its antecedents. Arthritis Res Ther 2005, 7: R92-R1000.

78. Glass JM, Lyden A, Petzke F, Clauw D: The effect of brief exercise on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 2004, 57: 391-398.

79. Okifuji A, Turk DC: Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J Pain 2006, 7: 657-667.

80. Macfarlane TV, Blinkhorn A, Worthington HV, Davies RM, Macfarlane GJ: Sex hormonal factors and chronic widespread pain: a population study among women. Rheumatology 2002, 41:454-457.

81. Klein R, Berg PA: High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res 1999, 4:121-126.

82. Klein R, Bänisch M, Berg PA: Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology 1992, 17: 593-598.

83. Werle E, Fischer HP, Müller A, Fehn W, Eich W: Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol 2001, 28:595-600.

84. Wilson RB, Gluck OS, Tesser JR, Rice JC, Meyer A, Bridges AJ: Antipolymer antibody reactivity in a subset of patients with fibromyalgia correlates with severity. J Rheumatol 1998, 26: 402-407.

85. Nishikai M, Tomomatsu S, Hankins RW, Takagi S, Miyachi K, Kosaka S, Akiya K: Autoantibodies to a 68/64 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hyperosmia and cognitive disorders. Rheumatology 2001, 40:806-810.

86. Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Increased cerebrospinal fluid levels of substance P in patients with fibromyalgia. J Rheumatol 2005, 32: 1787-1793.

87. Evengard B, Nilsson CG, Lindh G, Lindquist L, Eneroth P, Fredriksson O, Malmlöf C, Crielaard JM: Plasma tryptophan and other amino acids in fibromyalgia/fibrositis syndrome. J Rheumatol 1999, 26:1554-1569.

88. Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L: Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene related peptide (CGRP). J Rheumatol Suppl 1989, 19:34-97.

89. Hocherl K, Farber L, Ladenburger S, Vosshage D, Stratz T, Muller W, Grobeker H: Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia [in process citation]. Scand J Rheumatol Suppl 2000, 113:46-48.

90. Russell U, Michalek JE, Vipraio GA, Fletcher EM, Wall K: Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989, 16:158-163.

91. Wallace D, Bowman RL, Wormsley SB, Peter JB: Cytokines and immune regulation in patients with fibrositis. Arthritis Rheum 2003, 49:1334-1335.

92. Wallace D, Bowman RL, Wormsley SB, Peter JB: Cytokines and immune regulation in patients with fibrositis. Arthritis Rheum 2003, 49:1334-1335.

93. Gur A, Karakoc M, Nas K, Remzi, Cevik, Denli A, Sarac J: Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002, 29:358-361.

94. Sarchielli P, Alberti A, Floridi A, Gallai V: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000, 87:201-211.

95. Staub R, Robinson ME, Price DD: Isometric exercise has opposite effects on central pain mechanisms in fibromyalgia patients compared to normal controls. Pain 2005, 118:176-184.

96. Sarchielli P, Alberti A, Floridi A, Gallai V: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000, 87:201-211.

97. Alpar EK, Onuoha G, Killampilv VV, Waters R: Management of chronic pain in whiplash injury. J Bone Joint Surg Br 2002, 84: 807-811.

98. Giovengo SL, Russell U, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1554-1569.

99. Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L: Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene related peptide (CGRP). J Rheumatol Suppl 1989, 19:34-97.

100. Alpar EK, Onuoha G, Killampilv VV, Waters R: Management of chronic pain in whiplash injury. J Bone Joint Surg Br 2002, 84: 807-811.

101. Wallack BJ, Wallace JB: All about Fibromyalgia. New York: Oxford University Press; 2001.

102. Sandberg M, Larsson B, Lindberg LG, Gerdle B: Different patterns of blood flow response in the trapezius muscle following needle stimulation (acupuncture) between healthy subjects and patients with fibromyalgia and work-related trapezius myalgia. Eur J Pain 2005, 9:497-510.

103. Montoya P, Pauli P, Batra A, Wiedemann G: Altered processing of pain-related information in patients with fibromyalgia. Eur J Pain 2005, 9:293-303.

104. Landis CA, Lentz MJ, Tsuij J, Buchwald D, Shaver JL: Pain, psychological variables, sleep quality, and natural killer cell activity in midlife women with and without fibromyalgia. Brain Behav Immun 2004, 18:304-313.

105. Perretet D, Crosier JL, Denisovet D, Crielaard JM: Pressure pain thresholds of tender point sites in patients with fibromyalgia and in healthy controls. Eur J Pain 2004, 8:111-117.

106. Geiser ME, Casey KL, Brucksh CB, Ribbens CM, Appleton BB, Crofton LJ: Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain 2003, 103:243-250.

107. Embreg M, Lundeberg T, Kopp S: Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia. Pain 2003, 101:278-282.

108. Carli G, Suman AL, Biasi G, Marcolongo R: Hyperventilation and other putative biochemical markers in serum patients compared to normal controls. Pain 2003, 103:243-250.

109. Crofford LJ: Effect on prostaglandin E2 and leukotriene B4 levels by local site effects on central pain mechanisms in fibromyalgia. Pain 2000, 85:29-36.

110. Graven-Nielsen T, Aspengren Kendall S, Henriksen KG, Bengtsen M, Sorensen J, Johnson A, Gerdle B, Arendt-Nielsen L: Keta- mine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:493-499.

111. Embreg M, Lundeberg T, Kopp S: Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. Pain 2000, 85:31-39.

112. Embreg M, Hedenberg-Magnussson B, Alstergren P, Kopp S: The
level of serotonin in the superficial masseter muscle in relation to local pain and allodynia. Life Sci 1999, 65:313-325.

116. McDermid AJ, Rollman GB, McCuin GA: Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification. Pain 1995, 66:139-144.

117. Kosek E, Ekhholm J, Hansson P: Increased pressure pain sensitivity in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain 1995, 63:335-339

118. Tukey E, McCuin GA, Hart LE, Teasell RW, Goldsmith CH, Rollman GB, McDermid AJ, DeShane PJ: The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol 1995, 22:944-952.

119. Wiiffe F, Ross K, Anderson J, Russell UJ: Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995, 22:151-156.

120. Lautenbacher S, Rollman GB, McCuin GA: Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain 1995, 66:139-144.

121. Granges G, Littlejohn G: Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia. Arthritis Rheum 1993, 36:642-646.

122. Lautenschlager PJ, Seglias J, Brucke W, Muller W: Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia. Clin Rheumatol 1991, 10:168-173.

123. Petzke F, Harris RE, Williams DA, Clauw DJ, Gracely RH: Differences in unpleasantness induced by experimental pressure pain between patients with fibromyalgia and healthy controls. Eur J Pain 2005, 9:325-335.

124. Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Williams DA, Clauw DJ: Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 2004, 50:613-623.

125. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ: Subgrouping of fibromyalgia patients based on pressure pain thresholds and psychological factors. Arthritis Rheum 2003, 48:2916-2922.

126. Gracely RH, Petzke F, Wolf JM, Clauw DJ: Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002, 46:1333-1343.

127. Bendtsen L, Narregaard J, Jensen R, Olesen J: Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum 1997, 40:98-102.

128. Lorenz J, Grasedyck K, Bromm B: Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. Electroencephalogr Clin Neurophysiol 1996, 100:165-168.

129. Arroyo JF, Cohen ML: Abnormal responses to electrocorticographic stimulation in fibromyalgia. J Rheumatol 1993, 20:1925-1931.

130. Yunus MB, Young CS, Saxe CD, Mountz JM, Aldag JC: Positron emission tomography in patients with fibromyalgia syndrome and healthy controls. Arthritis Rheum 2004, 51:513-518.

131. Chang L, Berman S, Mayer EA, Suyenobu B, Derbyshire S, Nalboff B, Vogt B, FitzGerald L, Mandelkern MA: Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003, 98:1354-1361.

132. Wik G, Fischer H, Finer B, Bragee B, Kristiansen M, Fredrikson M: Retrosplenial cortical deactivation during painful stimulation of fibromyalgic patients. Int J Neurosci 2006, 116:1-8.

133. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL: Hypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994, 37:1583-1592.

134. Korszun A, Sackett-Lundeen L, Papadopoulou E, Bruckeck C, Mastersson L, Engellard NC, Haus E, Demitrack MA, Crofford LJ: Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999, 26:2675-2680.

135. Malt EA, Olafsson S, Lund A, Unnn H: Factors explaining variance in perceived pain in women with fibromyalgia. BMC Musculoskelet Disord 2002, 3;12.

136. Valkineen H, Håkkinen K, Pakarinen A, Hannonen P, Håkkinen A, Airaksinen O, Niemistö L, Kraemer WJ, Alen M: Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia. Scand J Rheumatol 2005, 34:309-314.

137. Gur A, Cevik R, Sarac AJ, Colpan L, Em S: Hypothalamic–pituitary–gonadal axis and cortisol in young women with primary fibromyalgia: the potential roles of depression, fatigue, and stress disturbance in the occurrence of hypocortisolism. Ann Rheum Dis 2004, 63:1504-1506.

138. Lentjes EG, Griepe EN, Boerma JW, Romijn FP, de Kloet ER: Glucocorticoid receptors, fibromyalgia and low back pain. Pain 1998, 77(Suppl):159.

139. Catley D, Kaell AT, Kirschbaum C, Stone AA: A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. Arthritis Care Res 2000, 13:51-61.

140. McLean SA, Williams DA, Harris RE, Kop WJ, Groner KH, Ambrose K, Lyden AK, Gracely RH, Crofford LJ, Geisser ME, Sen A, Biswas P, Clauw DJ: Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 2005, 52:3660-3669.

141. Weisbecker I, Floyd A, Dedert E, Salmon P, Sephton S: Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology 2006, 31:312-324.

142. Dedert EA, Studts JL, Weisbecker I, Salmon PG, Banis PL, Sephton SE: Religiosity may help preserve the cortisol rhythm in women with stress-related illness. Int J Psychiatry Med 2004, 34:61-77.

143. Sephton SE, Studts JL, Hoover K, Weisbecker I, Lynch G, Ho I, McGuffin S, Salmon P: Biological and psychological factors associated with memory function in fibromyalgia syndrome. Health Psychol 2003, 22:592-597.

144. Nergaard M, Lin A, Bonnesen S, van Hunsel F, Van Gastel A, Delmeire L, Biond M, Bosmans E, Kenis G, Scharpé S: Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998, 98:328-335.

145. Torpy DJ, Papanicolaou DA, Lottisak AJ, Wilder RL, Chrousos GP, Pillemer SR: Responses of the sympathetic nervous system and the hypothalamic–pituitary–adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 2000, 43:872-880.